Harnessing CD8+CD28− Regulatory T Cells as a Tool to Treat Autoimmune Disease
Citations Over TimeTop 24% of 2021 papers
Abstract
T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4+ Treg population has been extensively characterized, as a result of defined phenotypic and functional readouts. In this review article, we discuss the development and biology of CD8+ Tregs and their role in murine and human disease indications. A subset of CD8+ Tregs that lack the surface expression of CD28 (CD8+CD28- Treg) has proved efficacious in preclinical models. CD8+CD28- Tregs are present in healthy individuals, but their impaired functionality in disease renders them less effective in mediating immunosuppression. We primarily focus on harnessing CD8+ Treg cell therapy in the clinic to support current treatment for patients with autoimmune or inflammatory conditions.
Related Papers
- → Autoimmunity and Heavy Metals(1994)85 cited
- → Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus.(2003)78 cited
- → Timing of immunosuppression in the natural history of autoimmune disease(1992)3 cited
- From autoimmunity to autoimmune disease(2012)
- → Autoimmunity(2010)